Breyanzi 2L LBCL Absent from December’s CHMP Highlights
Here is a brief preview of this blast: On Friday, December 16, the CHMP meeting highlights were released following Monday’s CHMP agenda. Of note, Breyanzi’s (BMS’s CD19 CAR-T) Type II Variation for 2L LBCL transplant-intended patients was absent from December’s CHMP meeting. Below, Celltelligence provides updated EU timelines for Breyanzi.